All In Biotech

NDA 218343 · Amneal

Potassium Phosphates In 0.9% Sodium Chloride

Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 26, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

21

6 Phase 3, 2 recruiting

FAERS reports

357

301 serious, 64 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2025.

Potassium Phosphates in Sodium Chloride Injection is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated. Potassium Phosphates in Sodium Chloride Injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient or contraindicated. ( 1 )

Mechanism: Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 26, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE · POTASSIUM PHOSPHATE, DIBASIC 1.18GM/250ML (4.72MG/ML); POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/250ML (4.48MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Potassium Phosphates In 0.9% Sodium Chloride" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea34
  • diarrhoea29
  • pneumonia25
  • vomiting24
  • dyspnoea22
  • hypotension22
  • cytokine release syndrome21
  • fatigue18
  • febrile neutropenia18
  • pyrexia18
  • sepsis18
  • asthenia16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200511
200623
200719
200812
200929
201028
201132
201222
20133
20156
20168
20172
20184
201919
202023
202125
202225
202322
20249
20259
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.